These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34224330)

  • 41. SARS-CoV-2 infection and the antiviral innate immune response.
    Yang H; Lyu Y; Hou F
    J Mol Cell Biol; 2020 Nov; 12(12):963-967. PubMed ID: 33377937
    [No Abstract]   [Full Text] [Related]  

  • 42. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19.
    Bernini R; Velotti F
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease.
    Todorović-Raković N; Whitfield JR
    Cytokine; 2021 Oct; 146():155637. PubMed ID: 34242899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
    Onodi F; Bonnet-Madin L; Meertens L; Karpf L; Poirot J; Zhang SY; Picard C; Puel A; Jouanguy E; Zhang Q; Le Goff J; Molina JM; Delaugerre C; Casanova JL; Amara A; Soumelis V
    J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33533916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunology Lessons from the SARS-CoV-2 Pandemic.
    Yokoyama WM; Hogquist KA; O'Shea JJ
    Annu Rev Immunol; 2021 Apr; 39():v-vii. PubMed ID: 33939926
    [No Abstract]   [Full Text] [Related]  

  • 48. A tale of two antiviral targets - and the COVID-19 drugs that bind them.
    Cully M
    Nat Rev Drug Discov; 2022 Jan; 21(1):3-5. PubMed ID: 34857884
    [No Abstract]   [Full Text] [Related]  

  • 49. Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
    Kiss N; Lőrincz K; Medvecz M; Fésűs L; Csuha P; Hermányi Z; Wikonkál NM
    Dermatol Ther; 2020 Nov; 33(6):e14186. PubMed ID: 32794375
    [No Abstract]   [Full Text] [Related]  

  • 50. Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.
    Tamir H; Melamed S; Erez N; Politi B; Yahalom-Ronen Y; Achdout H; Lazar S; Gutman H; Avraham R; Weiss S; Paran N; Israely T
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repurposing Revisited: Exploring the Role of Metformin for Treatment of COVID-19.
    Siedner MJ; Sax PE
    Clin Infect Dis; 2024 Aug; 79(2):292-294. PubMed ID: 38690870
    [No Abstract]   [Full Text] [Related]  

  • 53. Virus-, host-, immune-based targets for COVID-19 therapy.
    Liu W; Zhu HL; Duan Y
    Drug Discov Today; 2020 Dec; 25(12):2071-2073. PubMed ID: 33035666
    [No Abstract]   [Full Text] [Related]  

  • 54. Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus?
    Sen A
    Med Hypotheses; 2020 Nov; 144():110208. PubMed ID: 33254515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
    Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P
    Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
    Mohanty RR; Padhy BM; Das S; Meher BR
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2802-2807. PubMed ID: 33829465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato's Cave.
    Kontoghiorghes GJ; Kolnagou A; Fetta S; Kontoghiorghe CN
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
    Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.